NCT02526745View on ClinicalTrials.gov

Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

July 31, 2016

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

the vaccine with high doses of virus content between 4.7～5.0 lgPFU

BIOLOGICAL

the vaccine with low doses of virus content between 4.7～5.0 lgPFU

BIOLOGICAL

the vaccine with high doses of virus content between 4.3～5.0 lgPFU

BIOLOGICAL

the vaccine with middle doses of virus content between 4.3～5.0 lgPFU

BIOLOGICAL

the vaccine with low doses of virus content between 4.3～5.0 lgPFU

BIOLOGICAL

placebo

All Listed Sponsors
lead

Beijing Chaoyang District Centre for Disease Control and Prevention

OTHER

NCT02526745 - Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older | Biotech Hunter | Biotech Hunter